Celgene charged with fraudulent promotion of cancer drugs Thalidomid and Revlimid

Celegene Corporation has been charged by whistleblower former company Salesperson Beverly Brown, with fraudulently promoting and marketing its cancer drugs Thalidomid and Revlimid in ways not approved by the FDA.

Ms. Brown,  said in a Federal Court Complaint that patients and medical advisors were denied appropriate warnings provided in a package insert.

Ms. Brown claims that Celgene’s conduct caused the Government to pay millions in Medicare and Medicaid for prescriptions of when other treatments worked better.

Celgene profited by persuading and sometimes paying doctors to substitute its untried remedies for treatments proven to be safe, she said in her Complaint.